Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 80.000 / 1.672M |
Day Range | - - - |
52 Wk Range | 1.610 - 7.450 |
Market Cap | $1.659B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 1.57% |
Days to Cover | 1.01 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Immunome (NASDAQ:IMNM), Gyre Therapeutics (NASDAQ:GYRE), 4D Molecular Therapeutics (NASDAQ:FDMT), Syndax Pharmaceuticals (NASDAQ:SNDX) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Truist Securities on Monday, March 18, 2024. The analyst firm set a price target for 10.00 expecting AUTL to rise to within 12 months (a possible 60.26% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $6.24 last updated March 27, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.